Back HIV Prevention

AIDS 2016: Australia Adopts Ambitious Plan to Use PrEP to "Virtually Eliminate" HIV

Australia plans an ambitious program of pre-exposure prophylaxis (PrEP) provision for gay men at high risk of HIV, with the aim of "virtually eliminating" HIV in the gay community by 2020, Iryna Zablotska from the University of New South Wales told delegates at the 21st International AIDS Conference (AIDS 2016) this week in Durban. PrEP roll-out is also underway in some countries in Kenya and South Africa.

alt

Read more:

AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance Therapy

A pair of long-acting injectable antiretrovirals -- cabotegravir and rilpivirine -- administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load, according to 48-week results from the LATTE-2 trial presented at the 21st International AIDS Conference (AIDS 2016) this week in Durban. A related qualitative analysis showed that study participants preferred long-acting injectables over pills for several reasons.

alt

Read more:

Mild Neurological Impairment Is Common During Early HIV Infection

People with HIV infection often have neurological signs and symptoms very soon after becoming infected -- even before they develop antibodies that show up on a test -- but these are typically mild to moderate and resolve after starting effective antiretroviral therapy (ART), according to a study published in the June 10 advance online edition of Neurology. These findings provide further evidence for starting treatment as soon as possible after HIV diagnosis.

alt

Read more:

AIDS 2016: Young Gay Men Can Do Well on PrEP, But May Need More Support

Young gay and bisexual men had good adherence to Truvada for pre-exposure prophylaxis (PrEP) during the first few months of a demonstration project with close monitoring, but adherence slipped once follow-up switched from monthly to quarterly, suggesting that young people using PrEP may require more on-going support, according to a presentation at the 21st International AIDS Conference (AIDS 2016) this week in Durban.

alt

Read more:

HIV Treatment Reduces HIV Transmission by 77% among South African Couples

Antiretroviral treatment reduced the risk of HIV transmission by 77% in serodiscordant couples in rural South Africa, a population-based study carried out in the province of KwaZulu-Natal has shown. The findings were recently published in the advance online edition of Clinical Infectious Diseases. The investigators say that their findings provide a real-life estimate of the impact of antiretroviral treatment on HIV transmission under normal community conditions.

alt

Read more:

AIDS 2016: PrEP Can Further Reduce HIV Risk After Partner Starts Antiretroviral Treatment

Offering Truvada pre-exposure prophylaxis (PrEP) to the HIV-negative partner in a serodiscordant couple during the first 6 months after the HIV-positive partner starts antiretroviral therapy (ART) can serve as a "bridge" to further reduce the likelihood of HIV infection, researchers reported at the 21st International AIDS Conference (AIDS 2016) taking place this week in Durban, South Africa.

alt

Read more:

ART Reduces Opportunistic Illnesses in Children and Adults with HIV

A pair of comprehensive reviews supported by the World Health Organization (WHO) have found that prompt initiation of antiretroviral therapy (ART) is associated with a lower risk of developing opportunistic infections and other HIV-related illnesses in children and adults living with HIV. Both reviews were published in the June 15 edition of Clinical Infectious Diseases.

alt

Read more:

AIDS 2016: Young Women Treated Very Early Stay HIV Negative and Preserve Immune Function

A group of youngSouth African women who were diagnosed during very HIV early infection and immediately given antiretroviral therapy (ART) preserved their CD4 cell counts and the function of cells that HIV normally disrupts, according to a study presented at the 2016 Towards an HIV Cure Symposium, which preceded the 21st International AIDS Conference this week in Durban, South Africa. The majority of them never seroconverted, staying HIV-negative despite having evidence of low levels of HIV infection in their cells.

alt

Read more:

Retention in Care Drives Adherence in PrEP Implementation Programs

The proportion of gay and bisexual men who started and remained on Truvada for pre-exposure prophylaxis (PrEP) varied in real-world implementation programs in 3 mid-size U.S. cities, but retention in care was "consistently suboptimal," according to a study described in the June 13 online edition of the Journal of the International AIDS Society. Among those who did remain in care, however, adherence was good.

alt

Read more:

AIDS 2016: PrEP Use Exceeds 79,000 in U.S., But Some Groups Lagging Behind

More than 79,000 people in the U.S. have started Truvada for pre-exposure prophylaxis (PrEP) over the past 4 years, according to the latest results from a survey of retail pharmacies by Gilead Sciences, presented today at the 21st International AIDS Conference (AIDS 2016) in Durban. Yet while large gains in PrEP use have been seen among men in cities with large gay communities, some groups are not benefitting as much as they could.

alt

Read more:

Many U.S. Communities Vulnerable to HIV Outbreaks Due to Unsafe Opioid Injection

Research published recently in the online edition of the Journal of Acquired Immune Deficiency Syndromes has identified the jurisdictions in the U.S especially vulnerable to the rapid spread of HIV or hepatitis C virus (HCV) due to unsafe injection drug use. A total of 220 countries in 26 states had a high level of vulnerability, with factors associated with unsafe injecting including unemployment, and poverty, and high rates of death due to drug overdose.

alt

Read more:

AIDS 2016: Researchers Now Focusing on Best Ways to Get PrEP to People Who Need It

Speaking to a pre-conference meeting on HIV pre-exposure prophylaxis (PrEP) ahead of the 21st International AIDS Conference (AIDS 2016), International AIDS Society president Chris Beyrer reminded delegates that when the International AIDS Conference was last held in Durban in the year 2000, the event was notable for drawing attention to the enormous gap in access to HIV treatment between rich and poorer countries. That conference began the treatment access era. "Now is really the time to start the PrEP access era," Beyrer said.

alt

Read more:

AIDS 2016: International AIDS Conference Coming Up in Durban

The 21st International AIDS Conference (AIDS 2016) will take place July 18-22 in Durban, South Africa, 16 years after the groundbreaking conference in the same city that put the spotlight on global access to new life-saving treatment for people living with HIV and AIDS. This year's theme -- Access, Equity, Rights Now -- recognizes the barriers that still need to be overcometo achieve universal access. HIVandHepatitis.com and collaborator Aidsmap.com will provide comprehensive on-site coverage starting July 18. Follow @HIVandHepatitison Twitter and see our AIDS 2016 conference page (coming soon) or Facebook page for the latest news.

alt

Read more:

AIDS 2016: Progress Towards 90-90-90 Targets is Promising, But Funding Is the Critical Step

The United Nations 90-90-90 targets for HIV testing, treatment, and viral suppression are achievable by 2020 in many high-burden countries, but donor retreat is now the biggest threat to widespread success, delegates agreed at the UN 90-90-90 Target Workshop ahead of the 21st International AIDS Conference (AIDS 2016) in Durban.

alt

Read more:

AIDS 2016: Second Durban Declaration Highlights Key Advances and Barriers

In advance of the 21st International AIDS Conference (AIDS 2016), starting July 18 in Durban, South Africa, the International AIDS Society has released the Second Durban Declaration, highlighting the 5 key scientific advances in the HIV field and 5 key structural barriers that have yet to be overcome.

alt

Read more:

AIDS 2016: Gains in Curbing HIV Could Be Lost Without Continued Commitment

Participants at the 21st International AIDS Conference (AIDS 2016), taking place this week in Durban, South Africa, reviewed the remarkable gains that have been made in access to HIV treatment and new prevention tools since the conference was last held here 16 years ago. But researchers, activists, and government leaders agreed that this progress could be reversed if stakeholders do not commit to increased funding and respect for the human rights of key populations at risk.

alt

Read more:

ASM Microbe 2016: New Integrase Inhibitor Bictegravir Looks Promising in Early Studies

Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favorable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity in laboratory and human studies, according to a set of posters presented at ASM Microbe 2016 last month in Boston.

alt

Read more:

AIDS 2016: International AIDS Conference Starts Next Week in Durban

The 21st International AIDS Conference (AIDS 2016) opens next Monday, July 18, in Durban, South Africa, 16 years after the groundbreaking conference in the same city that put the spotlight on global access to new life-saving treatment for people living with HIV and AIDS. This year's theme -- Access, Equity, Rights Now -- recognizes the barriers that still need to be overcometo achieve universal access. HIVandHepatitis.comand collaborator Aidsmap.comwill provide on-site coverage starting on July 17. Follow @HIVandHepatitison Twitter and visit our AIDS 2016 conference page (coming soon) or Facebook pagefor the latest news.

alt

Read more:

Coverage of ASM Microbe 2016 (ICAAC 2016)

HIVandHepatitis.com coverage of ASM Microbe 2016 -- a new conference incorporating the American Society for Microbiology annual meeting and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) -- Boston, June 16-20, 2016.

Highlights of this year's conference include antiretroviral drugs and treatment strategies, HIV pre-exposure prophylaxis (PrEP), microbiome research, antibiotic resistance, and emerging viruses including Zika.

Full coverage listing by topic

ASM Microbe 2016 website

7/1/16

alt

ASM Microbe 2016: Switching from Tenofovir DF to TAF Improves Bone and Kidney Safety

People with HIV who switched from the older tenofovir disoproxil fumarate (TDF) formulation to tenofovir alafenamide (TAF) were more likely to maintain viral load suppression and showed improvements in bone density and kidney function biomarkers, according studies presented at the 2016 ASM Microbe conference last month in Boston.

alt

Read more:

ASM Microbe 2016: HIV Seroconversion Is Rare If PrEP Is Used Consistently

New HIV infections occurred at a low rate of about 1 per 100 person-years among people who took Truvada for pre-exposure prophylaxis (PrEP), with seroconversions mostly seen in those who stopped taking their pills, according to an analysis of more than 30 studies and demonstration projects presented last week at the ASM Microbe 2016 conference in Boston.

alt

Read more: